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ORIGINAL RESEARCH
Objective: To verify whether depression, defined as a 15-item Geriatric Depression Scale
(GDS) > 6, is associated with greater drug utilization by elderly patients.
Population: 2568 patients enrolled in the Gruppo Italiano di Farmacovigilanza nell’Anziano
(GIFA) study.
Main outcome measure: Polypharmacy, ie, the daily use of at least 3 drugs, excluding
antidepressant and anxiolytic agents, in the month prior to admission.
Method: Home therapy data were collected according to a validated procedure. Correlates of
polypharmacy were assessed by logistic regression analysis in the whole population and in
subgroups for which indexes of disease severity were available.
Results: GDS > 6 was found to be positively correlated with polypharmacy (odds ratio 1.22;
95% confidence interval 1.01–1.48) as were older age, comorbidity, hypertension, diabetes
mellitus, congestive heart failure, and renal failure. Negative correlates of polypharmacy were
smoking habit and alcohol consumption, and GDS > 6 was negatively associated with the use
of analgesic (11.8% vs 15.6%, p = 0.012). In the subgroups with congestive heart failure and
chronic renal failure, GDS > 6 was strictly associated with greater disease severity, but did not
correlate with polypharmacy in multivariable models including indexes of disease severity.
Conclusions: Depressed mood is associated with polypharmacy in the broad elderly
population. However, when indexes of disease severity were considered, the association
was lost, indicating that depression is a marker of the burden of disease and does not increase
drug consumption per se.
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Introduction
The elderly are the greatest consumers of drugs in western countries: the daily
consumption of drugs rises from 2.0 ± 1.9 for people aged 65–74 years to 2.5 ± 2.0
for people aged 75 and over (Chen et al 2001). Polypharmacy has important economic
implications and dramatically increases the risk of adverse drug reactions (Carbonin
et al 1991; Onder et al 2002; Williams et al 2004). Reducing the number of drugs and
rationalizing their utilization, possibly implementing a nonpharmacological approach,
is a key component of interventions aimed at improving prescription (Williams et al
2004). Clarifying the determinants of the relationship between age and polypharmacy
would be introductory to these kinds of interventions. The age-related increase of
concurrent diseases (polypathology) seems the most obvious explanation of the high
number of drugs taken by older people, but additional factors deserve consideration.
Among these, the perceived need of care could affect the use of drugs, and the finding
of a positive association between depression and polypharmacy in an elderly
population supports this hypothesis (Simons et al 1992). However, the possibility
that depression simply reflects polypathology and/or increases the use of psychotropic
drugs only has not been tested. Furthermore, the role of social and cultural factors
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and individual age-related chronic diseases in conditioning
the relationship between age and drug use has not been
extensively assessed (Simons et al 1992; Al-Windi et al
2004).
The present study aims to identify the main correlates
of polypharmacy in a broad elderly population, and to verify
whether depression affects drug use per se or as an index of
polypathology and poor health status.
Method
Patients
The present study uses data from a large observational
study group, the Gruppo Italiano di Farmacovigilanza
nell’Anziano (GIFA), a collaborative group based in
community and university hospitals located throughout Italy.
GIFA periodically surveys drug consumption, occurrence
of adverse drug reactions, and quality of hospital care. We
used data of patients admitted consecutively to the 24
participating centers during the 4-month survey carried out
in 1998. Methods of GIFA have been previously described
(see Carbonin et al 1991; Carosella et al 1999). Briefly, a
study physician with specific training completed a
questionnaire for each patient on admission to hospital and
updated it daily. Data recorded included sociodemographic
characteristics, medical variables, complete blood count, and
neuropsychological and physical function variables.
Overall, 3010 patients were enrolled in the survey
period. We excluded patients who died during their hospital
stay (n = 117) and those who were unable to complete the
15-item Geriatric Depression Scale (GDS) score (n = 325),
eg, those with severe cognitive deficit. The final sample of
patients was 2568.
The main outcome measure of the study was the daily
use of 3 or more drugs prior to admission, where 3
correspond to the 75th percentile of the number of drugs’
distribution. Information on drug therapy in people with
cognitive impairment was collected by caregivers. Drugs
were coded by Anatomical and Therapeutic Classification
(ATC) (Pahor et al 1994).
Variables specifically considered in this study were age,
gender, smoking habits, and alcohol consumption. The
presence of depressive symptoms was ascertained using the
GDS, and patients with a GDS score greater than 6 were
considered depressed (Lesher and Berryhill 1994).
Functional and cognitive capabilities were measured by the
Activities of Daily Living (ADL) scale (Katz et al 1963)
and Hodgkinson Abbreviated Mental Test (AMT)
(Jitapunkul et al 1991), respectively. Patients having an AMT
score of 7 or less were considered cognitively impaired
(Rocca et al 1992). Diagnoses were coded according to
International Classification of Diseases, Clinical
Modification 9th revision (ICD-9 CM) (WHO 1980).
Having more than 4 diagnoses was considered as an index
of cumulative comorbidity. Furthermore, highly prevalent
age-related chronic conditions that may increase the
consumption of drugs, such as hypertension, diabetes
mellitus, congestive heart failure, cerebrovascular disease,
chronic obstructive pulmonary disease, and chronic renal
failure were also considered as potential confounders.
Procedures conformed to guidelines provided by the
Catholic University Ethical Committee.
Statistical analysis
Contingency tables were used to compare the demographic
and clinical characteristics of patients grouped according
to whether they used less than 3, or 3 or more drugs daily in
the month prior to admission. Odds ratios (OR) and the
corresponding 95% confidence intervals (CI), adjusted for
age and gender to quantify the association between the use
of 3 or more drugs and the variables of interest were used.
We then built a multivariable logistic regression model to
obtain a deconfounded estimate of the association between
depressive symptoms and polypharmacy, adjusting for age,
gender and variables proven to be associated with the
outcomes in the crude analysis. In a former model, anxiolytic
and antidepressant drugs were excluded from the definition
of polypharmacy to focus on the utilization of drugs
unrelated to depression. Anxiolytics were excluded because
of the high prevalence of anxious symptoms in elderly
depressed patients (Lenze et al 2001).
One of our objectives was to evaluate whether depression
was associated with polypharmacy independent from disease
severity. To test this hypothesis, we repeated the analysis
described above in people with congestive heart failure as
the main disease (ICD-9 codes 428–428.9 and 429.9) using
the New York Heart Association (NYHA) class as a marker
of disease severity. It was also repeated in people with
chronic renal failure as the main disease (ICD-9 codes 580.9,
581.9, 582–583.7, 585, 586, 588–588.9, 593.9), using the
Modification of Diet in Renal Disease (MDRD) derived
glomerular filtration rate (GFR) (Levey et al 1999) as an
index of disease severity. GFR was expressed as mL/min/
1.73 m2 body surface area (BSA). BSA was calculated by
Mosteller’s formula (Mosteller 1987). All analyses were
performed using SPSS V10.0 (SPSS Inc, Chicago IL, USA).Therapeutics and Clinical Risk Management 2005:1(1) 57
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Results
Demographic and clinical characteristics of patients divided
according to the number of daily used drugs in the last month
before the admission are shown in Table 1. Consumers of 3
or more drugs were older and more frequently depressed
than consumers of less than 3 drugs. Having more than 4
diagnoses was more frequent among those taking more
drugs, as were the diagnoses of hypertension, diabetes
mellitus, congestive heart failure, and renal failure. Similar
results were obtained including antidepressant and
anxiolytic agents in the computation of the number of drugs.
The multivariable logistic regression model showed that
a GDS > 6 is an independent correlate of polypharmacy,
together with age, male gender, comorbidity, hypertension,
diabetes mellitus, congestive heart failure, and chronic renal
failure. Negative correlates of the outcome were smoking
habit and alcohol consumption (Table 2). The association
between depressive symptoms and polypharmacy was
stronger when both antidepressant (ATC codes N06A) and
anxiolytic (ATC codes N05B) agents (OR 1.30; 95% CI
1.07–1.59) were included in the computation of used drugs.
When the analysis was limited to patients aged 65 or more,
we found a similar association, although with wider CI due
to the smaller sample (OR 1.24; 95% CI 0.96–1.64). To
verify whether the relationship between depression and
polypharmacy was modified by gender, we used a stratified
analysis and calculated the relative odds ratio (ROR) along
Table 1 Sociodemographic and clinical characteristics of patients divided according to the number of daily used drugs prior to
admission. Antidepressant and anxiolytic drugs were excluded from the computation.
Used drugs < 3 Used  drugs > 3
Characteristics N = 979 (%) N = 1589 (%) OR
a 95% CI
Age, years
< 65 406 41.5 442 27.8 1.0
65–79 351 35.9 723 45.5 1.92 1.60–2.32
> 79 222 22.7 424 26.7 1.83 1.48–2.27
Gender (Males) 535 54.6 910 57.3 1.20 1.02–1.42
Smokers 220 22.5 167 10.5 0.43 0.34–0.54
Alcohol consumption > ½ L 279 28.5 357 22.5 0.68 0.56–0.82
AMT < 7 169 17.3 309 19.4 1.02 0.82–1.27
Dependent in at least 1 ADL 77 7.9 188 11.8 1.39 1.05–1.85
GDS > 6 245 25.0 486 30.6 1.26 1.05–1.52
Having more than 4 diagnoses 331 33.8 873 54.9 2.23 1.88–2.64
Hypertension 293 29.9 690 43.4 1.74 1.47–2.07
Diabetes 136 13.9 368 23.2 1.85 1.49–2.31
Congestive heart failure 66 6.7 354 22.3 3.56 2.69–4.71
COPD 96 9.8 202 12.7 1.18 0.91–1.53
Cerebrovascular disease 129 13.2 231 14.5 1.0 0.76–1.23
Chronic renal failure 30 3.1 151 9.5 3.02 2.02–4.52
a Adjusted for age and gender.
Abbreviations: OR, odds ratio; CI, confidence interval; AMT, Hodgkinson Abbreviated Mental Test; ADL, activity of daily living; GDS, Geriatric Depression Scale;
COPD, chronic obstructive pulmonary disease.
Table 2 Summary regression model of selected risk factors to
the use of 3 or more drugs, excluded antidepressant and
anxiolytic agents, prior to admission
Risk factors OR 95% CI
Age, years
< 65 1.0
65–79 1.30 1.06–1.59
> 79 1.11 0.98–1.40
Gender (Males) 1.50 1.24–1.80
Smokers 0.42 0.33–0.53
Alcohol consumption > ½ L 0.76 0.62–0.93
Dependent in at least 1 ADL 1.33 0.98–1.80
Having more than 4 diagnoses 1.62 1.35–1.95
Hypertension 1.58 1.35–1.95
Diabetes 1.44 1.14–1.82
Congestive heart failure 3.20 2.39–4.29
Chronic renal failure 1.90 1.24–2.90
GDS > 6 1.22 1.01–1.48
Abbreviations: OR, odds ratio; CI, confidence interval; ADL, activity of daily
living; GDS, Geriatric Depression Scale.
with its 95% CI (Altman and Bland 2003). The OR was
1.44 (95% CI 1.09–1.90) in women and 1.20 (95% CI 0.89–
1.61) in men. The ROR was 1.2 (95% CI 0.80–1.80),
indicating no effect modification across gender.
Depressive symptoms were negatively associated with
the use of analgesic (ATC codes N02) and/or anti-
inflammatory (ATC codes M01A) drugs (16.6% in
depressed patients vs 19.8% in nondepressed patients,
p = 0.057).Therapeutics and Clinical Risk Management 2005:1(1) 58
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In the congestive heart failure (CHF) population
(n = 420), the prevalence of GDS > 6 progressively increased
through NYHA classes (I = 14.3%, II = 32.5%, III = 32.2%,
IV = 66.7%). NYHA class (III–IV vs I–II OR 2.75; 95% CI
1.11–6.83), but not the GDS > 6 (OR 1.14; 95% CI 0.73–
2.07), was an independent correlate of polypharmacy in this
subgroup. In the group with chronic renal failure (n = 181),
40% of patients with GFR < 60 mL/min/1.73 m2 BSA had
GDS > 6, compared with none of those having GFR ≥ 60 mL/
min/1.73 m
2 BSA. However, the prevalence of severe renal
impairment (ie, GFR < 30 mL/min/1.73 m2 BSA) was similar
in depressed (39.0%) and nondepressed (35.8%) renal
failure patients.
In this group, glomerular filtration rate < 30 mL/min/
1.73 m
2 BSA was associated with polypharmacy (OR 2.79;
95% CI 0.96–8.06, p = 0.059), while GDS > 6 was not
significantly related to the outcome.
In the whole study population, GDS > 6 was strongly
associated with comorbidity (32.7% in patients having 4 or
more diagnoses vs 24.7% in patients with less than 4 clinical
problems, p < 0.001) and physical performance (46.4% in
patients dependent in at least 1 ADL vs 26.4% in
independent subjects, p < 0.001).
Discussion
The main finding from our study is that depression is
associated with polypharmacy because it is a marker of
disease severity and health status impairment. The fact that
GDS > 6 was associated with a lesser consumption of
antiinflammatory and/or analgesic drugs suggests that
depression per se does not increase the perceived need of
care. The consumption of these drugs is considered to
depend consistently upon subjective factors, such as the
threshold for and the ability to cope with pain, which, in
turn, are expected to be influenced by the affective status
(Mantyselka et al 2002). This finding is apparently in
disagreement with the notion that pain threshold is reduced
in patients with depression (Marazziti et al 1998). However,
a more recent meta-analysis of 6 independent studies shows
that pain perception threshold is higher in depressed subjects
(Dickens et al 2003). Furthermore, elderly patients are
exposed to the risk of underrecognition and undertreatment
of pain because of a mix of cultural and procedural causes
(Won et al 1999; Schilling 2003). They may be unable to
explain their pain and to ask for care, and physicians have
been reported to give less attention to the medical problems
of older patients (Radecki et al 1988). All this might explain
our results.
Depression was found to be a main correlate of drug
consumption in Australian home-dwelling people aged over
59 (Simons et al 1992). However, the study did not assess
the relationship between polypharmacy and polypathology
or exclude antidepressant drugs. Furthermore, the diagnosis
of depression in the Australian study was clinical and not
based upon a screening instrument. This is likely to have
resulted in the selection of patients more severely depressed
than the ones we considered depressed using the GDS.
Accordingly, our results add to previous knowledge because
they apply to the average elderly population with chronic
diseases and stem from a deconfounded estimate of the
determinants of polypharmacy.
The findings indirectly confirm that geriatric depression
is usually reactive to medical distressing conditions (Hybels
et al 2001). Accordingly, a scale testing the affective status
can be regarded as a surrogate measure of perceived health
(Kennedy et al 2001). On the other hand, measures of
cognitive ability and physical dependency were not
correlated with the use of drugs, although they are well
recognized indexes of health status impairment (Nelson et
al 2004). This suggests an alternative explanation to the
relationship between consumption of drugs and affective
status: polypharmacy might negatively affect the perception
of disease status (Fincke et al 1998) and, as a consequence,
induce depression. Efforts to simplify the pharmacological
therapy might improve the affective status besides having
several other beneficial effects, eg, to reduce the risk of
adverse drug reactions (Schmader et al 2004; Williams et al
2004).
Alcohol and smoke addiction were associated with a
lesser consumption of drugs, and this is consistent with the
underreporting of medical problems or with a bias related
to the fact that patients in better health are less motivated to
correct unhealthy habits. Both these possibilities seem to
mediate, for example, the repeatedly reported link between
alcohol/smoke and underreporting/undertreatment of
hypertension (Gulliford 2001; Corsonello et al 2003).
Surveys on the quality of pharmacological therapy in
the elderly have provided conflicting results. Schmader et
al (2004) found that a considerable number of curable
conditions remained unrecognized and, then uncared for in
elderly outpatients, while geriatric evaluation and
management are able to reduce the number of conditions
with omitted drugs. Williams et al (2004), instead,
recognized an excess use of drugs as a relatively common
problem; however, they selected only elderly ambulatory
patients taking at least 5 drugs and thus obtained resultsTherapeutics and Clinical Risk Management 2005:1(1) 59
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that seem poorly representative of the average quality of
the pharmacological therapy. In the GIFA study, the use of
ACE inhibitors in CHF patients, antihypertensive in
hypertensive and statins in hypercholesterolemic patients
were found to be very inadequate (Sgadari et al 2000;
Antonelli Incalzi et al 2002; Onder et al 2003). Thus,
polypharmacy should not be equated to overuse of drugs,
rather it frequently means improper use (Gilberg et al 2003;
Hanlon et al 2004). Accordingly, efforts to understand
factors explaining polypharmacy could improve the quality
of drug prescription. Our findings suggest that depression
per se is not among the main explanatory factors.
Some limitations of this study should be cited. First, we
administered the GDS at the time of patient discharge. Thus,
the recorded score might not be fully representative of the
affective status prior to admission. Second, an index of
disease severity was not available for the whole studied
population: this prevented us from testing the hypothesis
that GDS > 6 reflected disease severity. However, the strong
relationship of GDS > 6 to dependency and comorbidity is
consistent with this hypothesis. All our patients were
hospitalized, and our results might not be generalizable to
the outpatients. However, our findings are supported by
others (Simons et al 1992) carried out in a non-
institutionalized population. Finally, a cross-sectional
observation is exploratory in nature and needs to be validated
prospectively.
In conclusion, our data indicate that although depression
is significantly related to polypharmacy, it seems not to affect
drug use per se, but rather as an index of polypathology and
poor health status. Clarifying both the causal link and the
determinants of the relationship between depression and
polypharmacy could help decrease the burden of both
pharmacological therapy and depression in elderly patients.
From this perspective, the psychological effects of strategies
simplifying pharmacological therapy should be explored.
In the same manner, it should be verified whether improving
the affective status by nonpharmacological interventions can
reduce drug consumption. Further studies would improve
our knowledge of the complex dynamics linking perceived
health and use of drugs in the elderly.
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